Does Rallies show 13F holders for RIGL?

Yes. Rallies tracks hedge fund and 13F ownership data for RIGL, including fund names, share counts, latest tracked quarter, and position changes when available.

Is RIGL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RIGL. It does not provide personalized investment advice.

RIGL (Rigel Pharmaceuticals Inc. (New)) Stock Analysis - Hedge Fund Holdings

Rigel Pharmaceuticals Inc. (New) (RIGL) is a publicly traded Healthcare sector company. As of May 21, 2026, RIGL trades at $28.93 with a market cap of $529.34M and a P/E ratio of 1.41. RIGL moved +2.08% today. Year to date, RIGL is -30.03%; over the trailing twelve months it is +43.24%. Its 52-week range spans $13.57 to $52.24. Analyst consensus is buy with an average price target of $54.00. Rallies surfaces RIGL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns RIGL stock?

Hedge funds tracked by Rallies that own RIGL include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Rigel Pharmaceuticals Inc. (New).

RIGL Key Metrics

Key financial metrics for RIGL
Metric	Value
Price	$28.93
Market Cap	$529.34M
P/E Ratio	1.41
EPS	$20.23
Dividend Yield	0.00%
52-Week High	$52.24
52-Week Low	$13.57
Volume	1
Avg Volume	0
Revenue (TTM)	$299.77M
Net Income	$364.23M
Gross Margin	93.39%

Top Hedge Funds Holding RIGL

Exoduspoint Capital holds 10.85K shares of RIGL, changed +64.86% as of Mar 31, 2026.

Latest RIGL News

Rigel Secures VEPPANU License with $70M Upfront, $320M Milestones — May 12, 2026
Rigel Pharmaceuticals Eyes Double-Digit Growth Below 60%, Finalizes R289 Phase II Dose — Mar 4, 2026
Rigel Projects Q4 EPS +66% to $1.33 on $69.8M Revenue, Estimate Revisions Surge — Feb 24, 2026

Recent RIGL Insider Trades

MOOS WALTER H sold 4.00K (~$145.44K) on Feb 20, 2026.
Schorno Dean L sold 1.73K (~$38.02K) on Feb 5, 2025.
Santos David A sold 1.80K (~$39.38K) on Feb 5, 2025.

RIGL Analyst Consensus

4 analysts cover RIGL: 0 strong buy, 2 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $54.00.

Common questions about RIGL

Who owns RIGL stock?: Hedge funds tracked by Rallies that own RIGL include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Rigel Pharmaceuticals Inc. (New).
Does Rallies show 13F holders for RIGL?: Yes. Rallies tracks hedge fund and 13F ownership data for RIGL, including fund names, share counts, latest tracked quarter, and position changes when available.
Is RIGL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RIGL. It does not provide personalized investment advice.